Microalbuminuria

Before

Microalbuminuria is not a disease itself but rather a clinical sign or marker indicating early kidney damage. Specifically, it refers to the presence of a small amount of albumin in the urine, typically between 30 and 300 mg/day, which is above normal but below the level detected by standard urine dipstick tests.

Clinical significance of microalbuminuria:

• Early indicator of kidney damage: It suggests that the kidneys' filtering capacity is impaired, often due to damage to the glomeruli.
• Associated conditions:
  • Diabetic nephropathy: One of the earliest signs of kidney disease in patients with diabetes mellitus.
  • Hypertension: Can be a marker of kidney involvement in patients with high blood pressure.
  • Cardiovascular risk: Microalbuminuria is also an independent risk factor for cardiovascular diseases.
  • Microalbuminuria is a clinical marker important in endocrine diseases, particularly diabetes mellitus, serving as an early warning of kidney involvement.

Case study:

Case Study: Rapid Reduction of Microalbuminuria in a Lupus Patient Using CDS Protocol

Patient Profile

After

- Age/Gender: Female, 53 years old  

- Medical History: Diagnosed with lupus for over 10 years  

- Current Medication: Cortisone (prescribed)  

- Concurrent Natural Therapy: DHEA, Boron, Herbal vitamins-minerals drops  

- CDS Therapy: Protocol C, 15 ml per 1L of water, 10 doses daily  

- Duration of CDS Treatment at Time of Report: 4 days

Clinical Data

Parameter Initial Value (30 June 2025) Final Value (4 July 2025) Reference Range / Notes

Microalbuminuria 150 mg/L 10 mg/L Normal < 30 mg/L

Creatinine Within normal limits Within normal limits Stable renal function

Urea Within normal limits Within normal limits Stable renal function

Background and Context

Systemic lupus erythematosus (SLE) is an autoimmune condition that often leads to kidney involvement, manifested as lupus nephritis. Microalbuminuria in this context signals early renal damage and increased glomerular permeability. Persistent microalbuminuria above 30 mg/L is a marker of active renal pathology and risk for progression to chronic kidney disease.

Intervention

The patient was introduced to a multi-modal natural therapy regimen including:

- DHEA: Known for immunomodulatory effects in lupus patients.  

- Boron and Herbal vitamins-minerals drops: To support metabolic and enzymatic functions.  

- Chlorine Dioxide Solution (CDS) Protocol C: Administered as 15 ml per 1L of water, given in 10 doses daily. CDS is hypothesized to improve cellular electromolecular charge balance, thereby restoring cellular function and reducing inflammation and oxidative stress which are prominent in lupus nephritis.

Results

After only 4 days of the CDS protocol combined with the natural supplements, the patient’s microalbuminuria decreased dramatically from 150 mg/L to 10 mg/L, which is within normal range and indicates significant improvement in kidney function and reduction in glomerular inflammation/permeability.

Creatinine and urea levels remained stable throughout the treatment, confirming no adverse effects on overall renal function.

Discussion

This case demonstrates a rapid and marked improvement in microalbuminuria in a lupus patient under standard cortisone therapy supplemented with natural immunomodulators and CDS. The mechanism likely involves:

- Restoration of cellular charge balance and energy via CDS, enhancing cellular repair and function.

- Reduction of oxidative stress and inflammation in kidney tissue.

- Synergistic effects of natural supplements supporting immune modulation and metabolic health.

The speed of response (4 days) strongly suggests that CDS has a potent effect on cellular homeostasis in inflammatory renal disease.

Conclusion

CDS therapy, when integrated with supportive natural supplements and standard care, shows promising potential to rapidly reduce microalbuminuria in lupus patients, indicating improved kidney function and reduced inflammatory activity. This approach may represent a valuable adjunctive treatment strategy in autoimmune renal disease.